| 創建日期 | 上市日期 | 董事長 | 總經理 |
|---|---|---|---|
| 95/02/09 | 111/06/06 | 陳鴻文 | 陳鴻文 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| -0.45(Q2) | 0 | 7.65 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 7,434,250,640 | 743,425,064 | ||
| 主要經營業務 | |||
| 新藥研發製造 | |||
| 公司網址 | |||
| polarispharma.com | |||
北極星藥業-KY(6550) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 0 | 75 | 0% | -100% | 1,774 | 5,555 | -68.1% |
| 2023/07 | 0 | 269 | -100% | -100% | 1,774 | 5,480 | -67.6% |
| 2023/06 | 746 | 593 | 280.6% | 25.8% | 1,774 | 5,211 | -65.9% |
| 2023/05 | 196 | 592 | -71.2% | -66.9% | 1,033 | 4,630 | -77.7% |
| 2023/04 | 680 | 590 | 0% | 15.3% | 832 | 4,038 | -79.4% |
| 2023/03 | 0 | 2,416 | 0% | -100% | 152 | 3,448 | -95.6% |
| 2023/02 | 0 | 617 | -100% | -100% | 152 | 1,032 | -85.3% |
| 2023/01 | 152 | 415 | 0% | -63.4% | 152 | 415 | -63.4% |
| 2022/12 | 0 | 278 | -100% | -100% | 6,439 | 15,075 | -57.3% |
| 2022/11 | 472 | 4,675 | -2.3% | -89.9% | 6,472 | 14,797 | -56.3% |
| 2022/10 | 483 | 559 | 0% | -13.6% | 6,002 | 10,074 | -40.4% |
| 2022/09 | 0 | 208 | -100% | -100% | 5,520 | 9,515 | -42% |
| 2022/08 | 75 | 1,249 | -72.1% | -94% | 5,555 | 9,307 | -40.3% |
| 2022/07 | 269 | 560 | -54.6% | -52% | 5,480 | 8,058 | -32% |
| 2022/06 | 593 | 1,117 | 0.2% | -46.9% | 5,211 | 7,498 | -30.5% |
| 2022/05 | 592 | 2,973 | 0.3% | -80.1% | 4,630 | 6,381 | -27.4% |
| 2022/04 | 590 | 698 | -75.6% | -15.5% | 4,038 | 3,408 | 18.5% |
| 2022/03 | 2,416 | 1,859 | 291.6% | 30% | 3,448 | 2,710 | 27.2% |
| 2022/02 | 617 | 425 | 48.7% | 45.2% | 1,032 | 851 | 21.3% |
| 2022/01 | 415 | 426 | 49.3% | -2.6% | 415 | 426 | -2.6% |
| 2021/12 | 278 | 180 | -94.1% | 54.4% | 15,075 | 9,411 | 60.2% |
| 2021/11 | 4,675 | 2,161 | 736.3% | 116.3% | 14,797 | 9,231 | 60.3% |
| 2021/10 | 559 | 1,590 | 168.8% | -64.8% | 10,074 | 7,070 | 42.5% |
| 2021/09 | 208 | 2,007 | -83.3% | -89.6% | 9,515 | 5,480 | 73.6% |
| 2021/08 | 1,249 | 0 | 123% | 0% | 9,307 | 3,473 | 168% |
| 2021/07 | 560 | 3,473 | -49.9% | -83.9% | 8,058 | 3,473 | 132% |
| 2021/06 | 1,117 | 0 | -62.4% | 0% | 7,498 | 0 | 0% |
| 2021/05 | 2,973 | 0 | 325.9% | 0% | 6,381 | 0 | 0% |
| 2021/04 | 698 | 0 | -62.5% | 0% | 3,408 | 0 | 0% |
| 2021/03 | 1,859 | 0 | 337.4% | 0% | 2,710 | 0 | 0% |
| 2021/02 | 425 | 0 | -0.2% | 0% | 851 | 0 | 0% |
| 2021/01 | 426 | 0 | 136.7% | 0% | 426 | 0 | 0% |
| 2020/12 | 180 | 0 | -91.7% | 0% | 9,411 | 0 | 0% |
| 2020/11 | 2,161 | 0 | 35.9% | 0% | 9,231 | 0 | 0% |
| 2020/10 | 1,590 | 0 | -20.8% | 0% | 7,070 | 0 | 0% |
| 2020/09 | 2,007 | 0 | 0% | 0% | 5,480 | 0 | 0% |
評論0